2019
Pioglitazone Therapy in Patients With Stroke and Prediabetes
Spence JD, Viscoli CM, Inzucchi SE, Dearborn-Tomazos J, Ford GA, Gorman M, Furie KL, Lovejoy AM, Young LH, Kernan WN. Pioglitazone Therapy in Patients With Stroke and Prediabetes. JAMA Neurology 2019, 76: 526-535. PMID: 30734043, PMCID: PMC6515584, DOI: 10.1001/jamaneurol.2019.0079.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedDiabetes Mellitus, Type 2Disease ProgressionFemaleGlycated HemoglobinHeart FailureHospitalizationHumansHypoglycemic AgentsInsulin ResistanceMaleMedication AdherenceMiddle AgedMyocardial InfarctionPioglitazonePrediabetic StateProportional Hazards ModelsRecurrenceSecondary PreventionStrokeConceptsAcute coronary syndromeStroke/myocardial infarctionTransient ischemic attackMyocardial infarctionCoronary syndromeHeart failureIRIS trialInsulin resistanceGood adherenceIschemic attackRecurrent strokeHazard ratioClinical trialsStroke/transient ischemic attackRandomized multicenter clinical trialAmerican Diabetes Association criteriaInsulin Resistance InterventionHemoglobin A1c levelsEffect of pioglitazoneInsulin-sensitizing agentsMulticenter clinical trialPlasma glucose levelsSerious bone fracturesPlacebo cohortPrior strokeAchievement of Guideline-Recommended Weight Loss Among Patients With Ischemic Stroke and Obesity
Dearborn JL, Viscoli CM, Young LH, Gorman MJ, Furie KL, Kernan WN. Achievement of Guideline-Recommended Weight Loss Among Patients With Ischemic Stroke and Obesity. Stroke 2019, 50: 713-717. PMID: 30786849, PMCID: PMC6391736, DOI: 10.1161/strokeaha.118.024008.Peer-Reviewed Original ResearchConceptsTransient ischemic attackBody mass indexProportion of patientsIschemic strokeMass indexVascular eventsBaseline weightWeight lossAchievement of guidelineDays of randomizationRecent ischemic strokeAcute ischemic strokeFuture vascular eventsIschemic attackPlacebo groupObese patientsDiabetes mellitusMedian ageTrial entryIRIS trialMedian timeFunctional outcomeInsulin resistanceClinical trialsPatients
2018
Distance from Home to Research Center: A Barrier to In-Person Visits but Not Treatment Adherence in a Stroke Trial
Leira EC, Viscoli CM, Polgreen LA, Gorman M, Kernan WN. Distance from Home to Research Center: A Barrier to In-Person Visits but Not Treatment Adherence in a Stroke Trial. Neuroepidemiology 2018, 50: 137-143. PMID: 29587267, PMCID: PMC5975097, DOI: 10.1159/000486315.Peer-Reviewed Original ResearchConceptsPerson visitsStroke trialsTreatment adherenceStudy centersInsulin Resistance InterventionLogistic regression modelsIndependent predictorsPreventive careClinical trialsOutcome measuresThird visitPatientsPlace of residenceResistance InterventionSecondary analysisYears of participationVisitsAdherenceGeneralizability of resultsTrialsRural areasTherapyDrugsRegression modelsRecruitment sites
2016
Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial
Viscoli CM, Inzucchi SE, Young LH, Insogna KL, Conwit R, Furie KL, Gorman M, Kelly MA, Lovejoy AM, Kernan WN, Investigators F. Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial. The Journal Of Clinical Endocrinology & Metabolism 2016, 102: 914-922. PMID: 27935736, PMCID: PMC5460686, DOI: 10.1210/jc.2016-3237.Peer-Reviewed Original ResearchConceptsTransient ischemic attackIschemic strokeFracture riskBone fracturesRisk/benefit ratioAbsolute fracture riskInsulin Resistance InterventionPlacebo-treated patientsIschemic attackNondiabetic patientsPlacebo groupCardiovascular riskBone healthStroke trialsNondiabetic participantsPrevent fallsClinical trialsRelative riskSafety dataFracture classificationQuarterly interviewsPioglitazonePatientsResistance InterventionRisk increment
2011
Boosting enrolment in clinical trials: validation of a regional network model
Kernan W, Viscoli C, Brass L, Amatangelo M, Birch A, Clark W, Conwit R, Furie K, Gorman M, Pesapane B, Kleindorfer D, Lovejoy A, Osborne J, Silliman S, Zweifler R, Horwitz R. Boosting enrolment in clinical trials: validation of a regional network model. Clinical Trials 2011, 8: 645-653. PMID: 21824978, PMCID: PMC3852692, DOI: 10.1177/1740774511414925.Peer-Reviewed Original ResearchConceptsClinical trialsTransient ischemic attackNames of patientsEligible patientsIschemic attackStroke preventionDrug adherenceStroke therapyActive surveillanceAverage monthly rateHome visitsPatientsHospitalTrial researchParticipant costsOutreach NetworkMultiple hospitalsTrialsStudy intervalNational InstituteEnrollmentMonthly rateStrokeParticipantsReproducible method
2005
Altruism as a reason for participation in clinical trials was independently associated with adherence
Rosenbaum JR, Wells CK, Viscoli CM, Brass LM, Kernan WN, Horwitz RI. Altruism as a reason for participation in clinical trials was independently associated with adherence. Journal Of Clinical Epidemiology 2005, 58: 1109-1114. PMID: 16223653, DOI: 10.1016/j.jclinepi.2005.03.014.Peer-Reviewed Original ResearchConceptsClinical trialsBetter functional statusStudy medicationMedical regimenRecruitment of participantsClinical featuresStroke trialsFunctional statusWomen's EstrogenStratified analysisMultivariable regressionClinical researchEstrogenTrialsAdherenceBaseline featuresSocial supportFurther investigationWomenParticipantsAltruistic reasonsPossible contributionHigh levelsPlaceboMedicationsDecline in Physical Performance Among Women With a Recent Transient Ischemic Attack or Ischemic Stroke
Kernan WN, Viscoli CM, Brass LM, Gill TM, Sarrel PM, Horwitz RI. Decline in Physical Performance Among Women With a Recent Transient Ischemic Attack or Ischemic Stroke. Stroke 2005, 36: 630-634. PMID: 15677573, DOI: 10.1161/01.str.0000155728.42847.de.Peer-Reviewed Original ResearchConceptsTransient ischemic attackIschemic strokePhysical performance testsPhysical performanceIschemic attackRecent transient ischemic attackRecent ischemic strokeRecurrent neurological eventsAbsence of recurrenceLong-term disabilityEstrogen therapyRecurrent strokePostmenopausal womenNeurological eventsClinical trialsPPT scoresBaseline scoresFunctional independenceStrokeSpecific interventionsSubsequent strokeWomenSustained declineScoresBaseline
2003
Influence of race, clinical, and other socio-demographic features on trial participation
Corbie-Smith G, Viscoli CM, Kernan WN, Brass LM, Sarrel P, Horwitz RI. Influence of race, clinical, and other socio-demographic features on trial participation. Journal Of Clinical Epidemiology 2003, 56: 304-309. PMID: 12767406, DOI: 10.1016/s0895-4356(03)00046-5.Peer-Reviewed Original ResearchConceptsTrial participationPrevious estrogen useClinical trial participationHistory of hysterectomyEstrogen useClinical characteristicsStroke trialsWomen's EstrogenClinical trialsConsent ratesCognitive impairmentSocio-demographic featuresMultivariate modelInfluence of raceHysterectomyEstrogenWomen's decisionsTrialsEthnic groupsImpairmentVisitsWomen
1997
Functional recovery after myocardial infarction in men: the independent effects of social class.
Ickovics JR, Viscoli CM, Horwitz RI. Functional recovery after myocardial infarction in men: the independent effects of social class. Annals Of Internal Medicine 1997, 127: 518-25. PMID: 9313019, DOI: 10.7326/0003-4819-127-7-199710010-00003.Peer-Reviewed Original ResearchConceptsBeta-Blocker Heart Attack TrialHeart Attack TrialMyocardial infarctionFunctional recoveryAttack TrialNew York Heart Association functional classPsychosocial factorsYork Heart Association functional classFunctional status 1 yearDouble-blind clinical trialCardiovascular-related illnessesPertinent prognostic factorsAcute myocardial infarctionIndependent effectsYears of agePrimary outcomePrognostic factorsClinical outcomesFunctional statusProspective dataClinical trialsInfarctionHigher social classMen 29Baseline assessment